…
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -87.93M | -83.57M | -60.23M | -41.02M | -21.44M |
| Net income | -87.87M | -78.06M | -68.25M | -43.59M | -21.44M |
| Selling general administrative | 26.79M | 32.02M | 28.84M | 18.70M | 9.71M |
| Gross profit | 19.89M | 52.30M | - | - | - |
| Reconciled depreciation | 5.32M | 5.41M | 4.21M | 1.73M | 0.39M |
| Ebit | -87.93M | -83.57M | - | - | - |
| Ebitda | -82.61M | -78.16M | - | - | - |
| Depreciation and amortization | 5.32M | 5.41M | - | - | - |
| Operating income | -96.01M | -88.90M | -78.49M | -44.64M | -23.95M |
| Other operating expenses | 121.22M | 141.20M | - | - | - |
| Interest expense | - | - | 0.00M | 0.10M | 0.30M |
| Tax provision | -0.06M | -5.51M | 8.03M | 2.57M | 0.00M |
| Interest income | 9.47M | 14.72M | 15.47M | 3.42M | 0.04M |
| Net interest income | 9.47M | 14.72M | 15.47M | 3.32M | -0.26M |
| Income tax expense | -0.06M | -5.51M | - | - | - |
| Total revenue | 25.21M | 52.30M | 44.76M | 17.20M | 0.24M |
| Total operating expenses | 115.91M | 141.20M | 123.25M | 61.84M | 24.19M |
| Cost of revenue | 5.32M | 5.41M | - | - | - |
| Total other income expense net | 8.09M | 5.33M | 2.80M | 0.29M | 2.76M |
| Net income from continuing ops | -87.87M | -78.06M | -68.25M | -43.59M | -21.44M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 221.10M | 324.60M | 364.84M | 414.49M | 141.99M |
| Other current assets | 4.43M | 8.40M | 4.64M | 3.49M | 0.27M |
| Total liab | 62.51M | 89.74M | 500.43M | 488.91M | 174.54M |
| Total stockholder equity | 158.60M | 234.86M | -135.58M | -74.43M | -32.54M |
| Other current liab | 6.72M | 8.42M | - | - | - |
| Common stock | 0.00M | 0.00M | - | - | - |
| Capital stock | 0.00M | 0.00M | 9.46M | 2.54M | 0.57M |
| Retained earnings | -310.87M | -223.00M | -144.94M | -76.69M | -33.10M |
| Cash | 41.72M | 27.39M | 140.60M | 184.44M | 39.30M |
| Total current liabilities | 22.93M | 37.31M | 68.86M | 48.54M | 25.17M |
| Current deferred revenue | 8.70M | 22.76M | - | - | - |
| Net debt | -1.06M | 18.39M | - | - | - |
| Short term debt | 6.03M | 5.59M | - | - | - |
| Short long term debt total | 40.66M | 45.78M | - | - | - |
| Other stockholder equity | 469.20M | 457.15M | - | - | - |
| Total current assets | 165.54M | 257.96M | 278.27M | 366.90M | 108.92M |
| Long term investments | 2.15M | 3.45M | 10.68M | 7.81M | 6.42M |
| Short term investments | 119.08M | 220.92M | 130.58M | 177.69M | 68.86M |
| Net receivables | 0.30M | 1.26M | 2.45M | 0.00M | - |
| Long term debt | - | - | - | - | 30.28M |
| Accounts payable | 1.49M | 0.53M | 1.79M | 2.01M | 1.35M |
| Accumulated other comprehensive income | 0.26M | 0.71M | - | - | - |
| Non currrent assets other | 6.03M | 5.54M | 5.25M | 6.07M | 4.10M |
| Non current assets total | 55.56M | 66.64M | 86.57M | 47.59M | 33.08M |
| Capital lease obligations | 40.66M | 45.78M | 48.23M | 18.57M | 18.65M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | 104.07M | -88.16M | 45.73M | -122.20M | -74.32M |
| Total cashflows from investing activities | 103.53M | -88.16M | - | - | - |
| Total cash from financing activities | -0.36M | 84.01M | 1.01M | 239.59M | 39.92M |
| Net income | -87.87M | -78.06M | -68.25M | -43.59M | -21.44M |
| Change in cash | 14.28M | -113.22M | -44.66M | 147.12M | -10.14M |
| Begin period cash flow | 32.63M | 145.85M | 190.51M | 43.40M | 53.53M |
| End period cash flow | 46.91M | 32.63M | 145.85M | 190.51M | 43.40M |
| Total cash from operating activities | -88.89M | -109.07M | -91.41M | 29.72M | 24.26M |
| Issuance of capital stock | 0.00M | 84.01M | 4.29M | 239.59M | 9.95M |
| Depreciation | 5.32M | 5.41M | 4.21M | 1.73M | 0.39M |
| Other cashflows from investing activities | 3.00M | - | - | - | - |
| Change to account receivables | 0.95M | 1.19M | -2.45M | 0.00M | - |
| Other cashflows from financing activities | -0.56M | - | - | - | - |
| Capital expenditures | 0.57M | 3.11M | 9.81M | 13.98M | 2.90M |
| Change in working capital | -22.09M | -59.67M | -26.43M | 69.49M | 46.26M |
| Stock based compensation | 11.85M | 16.20M | 6.92M | 1.96M | 0.38M |
| Other non cash items | 3.90M | 7.04M | 3.46M | 1.08M | 1.24M |
| Free cash flow | -89.47M | -112.19M | -101.22M | 15.75M | 21.35M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| MGX Metagenomi, Inc. Common Stock |
-0.02 3.43% |
0.66 | - | - | 3.23 | 0.40 | 0.71 |
| NVO Novo Nordisk A/S |
-0.80 1.91% |
40.80 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
-2.08 0.39% |
535.71 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
9.09 0.95% |
961.49 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Brian Charles Thomas Ph.D. | Co-Founder, CEO & Chairman of the Board | 1969 |
| Dr. Jian Irish M.B.A., Ph.D. | President, COO & Director | 1964 |
| Dr. Sarah B. Noonberg M.D., Ph.D. | Chief Medical Officer | 1968 |
| Dr. Jak Knowles M.D. | Co-Founder & Member of Scientific Advisory Board | NA |
| Ms. Pamela M. Wapnick M.B.A. | Chief Financial Officer | 1966 |
| Dr. Luis G. Borges Ph.D. | Chief Scientific Officer | 1962 |
| Mr. Matthew L. Wein J.D. | Vice President of Corporate Legal, Compliance & Corporate Secretary | 1971 |
| Dr. Alan Brooks Ph.D. | Senior Vice President of Preclinical | 1966 |
| Dr. Christopher Brown | Head of Discovery | 1989 |
| Dr. Jian Irish M.B.A., Ph.D. | CEO, President & Director | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.